The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes

被引:8
|
作者
Ceriello, Antonio [1 ,2 ]
De Nigris, Valeria [1 ]
Pujadas, Gemma [1 ]
La Sala, Lucia [1 ,2 ,3 ]
Bonfigli, Anna Rita [4 ]
Testa, Roberto [5 ]
Uccellatore, Annachiara [3 ]
Genovese, Stefano [3 ]
机构
[1] IDIBAPS, C Rossello 149-153, Barcelona 08036, Spain
[2] Hosp Clin Barcelona, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
[3] IRCCS Grp Multimed, Dept Cardiovasc & Metab Dis, Sesto San Giovanni, MI, Italy
[4] INRCA Ancona, Sci Direct, Ancona, Italy
[5] INRCA IRCCS Natl Inst, Expt Models Clin Pathol, Ancona, Italy
关键词
Type; 1; diabetes; GLP-1; Endothelial function; Oxidative stress; Metabolic memory; GLUCAGON-LIKE PEPTIDE-1; OXIDATIVE STRESS; DYSFUNCTION; VASODILATATION; ACTIVATION; MELLITUS; MARKERS; CELLS;
D O I
10.1016/j.diabres.2016.01.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To test the effect of normoglycemia and glucagon-like peptide-1 (GLP-1), alone or in combination, on the possible normalization of endothelial function in type 1 diabetes. Methods: Fifteen people with type 1 diabetes participated in three experiments: reaching and maintaining normoglycemia for 4 h; reaching and maintaining hyperglycemia plus GLP-1 infusion for 4 h; and reaching and maintaining normoglycemia for 4 h with simultaneous infusion of GLP-1. Results: Both normoglycemia and GLP-1 infusion restored endothelial function and decreased and plasma 8-iso prostaglandin F2 alpha levels. However, only the combination of normoglycemia and GLP-1 was able to normalize endothelial function. Conclusions: This study confirms that long-lasting hyperglycemia in type 1 diabetes induces a permanent alteration which contributes to maintaining endothelial dysfunction even when glycemia is normalized, and that in the presence of normoglycemia, GLP-1 can contribute to normalizing endothelial function. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:64 / 68
页数:5
相关论文
共 50 条
  • [1] Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes
    Ceriello, Antonio
    Kumar, Sudhesh
    Piconi, Ludovica
    Esposito, Katerine
    Giugliano, Dario
    DIABETES CARE, 2007, 30 (03) : 649 - 654
  • [2] GLP-1 agonists in type 1 diabetes
    Pettus, Jeremy
    Hirsch, Irl
    Edelman, Steven
    CLINICAL IMMUNOLOGY, 2013, 149 (03) : 317 - 323
  • [3] GLP-1 for type 2 diabetes
    Ahren, Bo
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1239 - 1245
  • [4] Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes
    Torekov, S. S.
    Kipnes, M. S.
    Harley, R. E.
    Holst, J. J.
    Ehlers, M. R.
    DIABETES OBESITY & METABOLISM, 2011, 13 (07): : 639 - 643
  • [5] GLP-1 Agonists in Type 1 Diabetes Mellitus
    Janzen, Kristin M.
    Steuber, Taylor D.
    Nisly, Sarah A.
    ANNALS OF PHARMACOTHERAPY, 2016, 50 (08) : 656 - 665
  • [6] GLP-1 Receptor as a Biomarker for Incretin Function in Type 2 Diabetes
    Rajan, Sindhu
    Ancsin, John B.
    Mathew, Elizabeth
    Janardanan, Jyothi
    Philipson, Louis
    DIABETES, 2013, 62 : A473 - A473
  • [7] Dynamics of plasma active GLP-1 versus insulin and glucose concentrations during GLP-1 infusion in rat model of postprandial hyperglycemia
    Eiki, Jun-ichi
    Yada, Toshihiko
    ENDOCRINE JOURNAL, 2011, 58 (08) : 691 - 698
  • [8] GLP-1 AND DPP-IV IN TYPE 1 DIABETES
    Dejgaard, T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A4 - A4
  • [9] A New Option for Type 1 Diabetes: GLP-1 Analogues
    Harrison, Lindsay B.
    Mora, Pablo
    Clark, Gregory
    Lingvay, Ildiko
    DIABETES, 2012, 61 : A597 - A597
  • [10] GLP-1 analogues in treatment of type 1 diabetes mellitus
    Toelle, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (42) : 2123 - 2126